diabetic ketoacidosis: The metabolic condition resulted from uncontrolled diabetes mellitus, in which the shift of acid-base status of the body toward the acid side because of loss of base or retention of acids other than carbonic acid is accompanied by the accumulation of ketone bodies in body tissues and fluids.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditions
|
142 |
3. Check pre-conditions, main-only, mode, registry filtersPre-conditions: EVENT_AGE<40 Registry filters: 0 out of 7 registries used, show all original rules. |
0 |
4. Check minimum number of eventsNone |
0 |
5. Include endpoints |
101 |
6. Filter based on genotype QC (FinnGen only) |
78 |
Control definitions (FinnGen only)
- Control exclude
- DIABETES_FG
- Control conditions
- not E4_DM2
and not PANCREATITIS
and not INSULIN_INTER_AND_LONG
and not KELA_DIAB_INSUL
and not INSULIN_SHORTFAST
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Type 1 diabetes, strict definition, subgroup 2
based on the number of shared cases.
Similar with more cases:
- Type 1 diabetes, wide definition, subgroup 2
- Type 1 diabetes, strict definition
- Type 1 diabetes, strict (exclude DM2)
- Type 1 diabetes, definitions combined
- Type 1 diabetes, wide definition
Similar with less cases:
None
Case counts by codes
↥FinnGen case counts by registry codes:
No data for upset plot.
No data for upset table.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1340 | 519 | 810 |
| Only index persons | 483 | 167 | 316 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 13.08 | 10.37 | 14.53 |
| Only index persons | 15.15 | 14.82 | 15.32 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 78 | 35 | 43 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 12.29 | 11.71 | 12.77 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 86
- Matched controls
- 860
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
103
Kela drug reimbursment
Diabetes, insulin-treated
+∞
123.8
86
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
+∞
99.1
75
*
A10AC01
ATC
insulin (human); parenteral
831.4
82.4
69
*
A10AB01
ATC
insulin (human); parenteral
+∞
80.2
64
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
+∞
63.6
53
*
A10AA01, ,
ATC
+∞
62.2
52
*
A10AA02, ,
ATC
+∞
62.2
52
*
A10AB05
ATC
insulin aspart; parenteral
1230.5
60.5
52
*
A10AB04
ATC
insulin lispro; parenteral
+∞
56.7
48
*
H04AA01
ATC
glucagon; nasal, parenteral
+∞
52.6
45
*
2500B
ICD-9 Finland
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
+∞
49.9
43
*
T89
ICPC
Diabetes insulin dependent
275.8
35.7
34
*
A98
ICPC
Health maint/preventive medicine
0.1
31.9
50
820
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
+∞
26.4
24
*
E10
ICD-10 Finland
Type 1 diabetes mellitus
+∞
26.4
24
*
A10AD01
ATC
insulin (human); parenteral
+∞
24.1
22
*
A10AE05
ATC
insulin detemir; parenteral
291.0
22.7
22
*
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
+∞
20.6
19
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
+∞
20.6
19
*
25000
ICD-8 Finland
Diabetes mellitus, Sine complicatione
+∞
19.5
18
*
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
+∞
18.4
17
*
SPAT1262
SPAT
Handing over of treatment supplies
19.0
16.3
25
18
A10AE04
ATC
insulin glargine; parenteral
+∞
13.9
13
*
XCK10
NOMESCO Finland
Photography of fundus of eye
59.7
13.3
15
*
H3600, E103,
ICD-10 Finland
+∞
11.7
11
*
Z13.1
ICD-10 Finland
Special screening examination for diabetes mellitus
124.6
10.7
11
*
A10AA03, ,
ATC
+∞
10.6
10
*
E10.8
ICD-10 Finland
Type 1 diabetes mellitus, With unspecified complications
+∞
10.6
10
*
OAB50, ,
SPAT
62.3
9.9
11
*
N02BE01
ATC
paracetamol; systemic, rectal
0.2
9.6
26
564
O24.0
ICD-10 Finland
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
111.8
9.6
10
*
T90
ICPC
Diabetes non-insulin dependent
99.4
8.6
9
*
H36.00
ICD-10 Finland
Diabetic background retinopathy
+∞
8.5
8
*
BEF00
NOMESCO Finland
Continuous subcutaneous glucose monitoring
+∞
8.5
8
*
CL2S4
NOMESCO Finland
Ocular fundus photography for diabetic retinopathy screening
87.3
7.5
8
*
CK2S4, ,
SPAT
+∞
7.4
7
*
E14.9
ICD-10 Finland
Unspecified diabetes mellitus, without complications
+∞
7.4
7
*
WX110
NOMESCO Finland
Infiltration anesthesia
0.3
6.9
28
538
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
0.3
6.9
24
501
M01AE01
ATC
ibuprofen; systemic, rectal
0.3
6.8
43
659
SAA02
NOMESCO Finland
Basic examination of mouth
0.3
6.6
31
559
C02EA02, ,
ATC
75.2
6.5
7
*
M01AB05
ATC
diclofenac; systemic, rectal
0.2
6.5
14
391
M01AH05
ATC
etoricoxib; oral
0.2
6.4
13
378
2501B
ICD-9 Finland
Diabetes mellitus, Diabetes with ketoacidosis[DIABETES MELLITUS CUM KETOACIDOSI ,TYYPPI I]
+∞
6.3
6
*
OAA67, ,
SPAT
0.0
6.1
*
144
205
Kela drug reimbursment
Chronic hypertension
9.1
6.1
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
43
67
11.84
29.71
5.2
2.2
1.33
267.03
mg/mmol
0.49
33
42
38
744
0.12
21.68
13.2
12.5
14.01
22.46
mg/l
1.75
24
555
48
771
0.15
17.14
15.7
12.9
63.83
69.64
umol/l
1.34
48
765
36
653
0.23
10.52
4.3
3.9
—
—
—
0
0
27
555
0.25
8.46
6.4
3.8
24.44
35.22
u/l
1.77
27
543
7
0
+∞
7.39
1.6
0.0
3.61
—
mmol/l
—
7
0
25
517
0.27
7.26
7.3
4.3
12.08
6.78
mm/h
1.59
25
499
0
126
0.00
5.47
0.0
1.9
—
3.60
—
0
93
40
609
0.36
5.18
10.3
9.0
94.79
95.57
ml/min/173m2
0.07
32
541
13
324
0.29
4.29
13.7
8.3
11.38
12.39
umol/l
0.20
13
314
14
322
0.32
3.83
3.6
3.0
—
—
estimate
—
0
0
0
93
0.00
3.76
0.0
1.7
—
3.73
—
0
61
36
209
2.24
3.19
3.3
1.5
2.40
1.30
u/ml
—
8
48
6
187
0.27
3.19
1.8
2.3
45.00
55.03
u/l
—
6
179
7
197
0.30
3.07
2.3
3.3
2.36
2.37
mmol/l
—
7
190
12
266
0.36
2.82
2.0
1.8
—
—
—
0
0
0
63
0.00
2.32
0.0
1.5
—
1105.01
—
0
50
0
63
0.00
2.32
0.0
1.2
—
—
—
0
0
13
246
0.44
1.97
8.7
8.7
37.23
38.14
g/l
0.33
13
241
9
186
0.42
1.78
3.9
2.7
—
—
—
0
0
14
236
0.51
1.46
7.4
5.0
—
—
—
0
0
0
40
0.00
1.37
0.0
1.4
—
33.88
—
0
40
0
40
0.00
1.37
0.0
1.6
—
67.37
—
0
32
0
41
0.00
1.35
0.0
1.1
—
—
—
0
0
0
41
0.00
1.35
0.0
1.8
—
3.40
—
0
30
0
41
0.00
1.35
0.0
1.1
—
—
—
0
0
0
41
0.00
1.35
0.0
1.3
—
—
—
0
0
0
36
0.00
1.17
0.0
1.4
—
1.16
—
0
22
0
36
0.00
1.17
0.0
1.4
—
1.35
—
0
22
0
36
0.00
1.17
0.0
1.4
—
1.04
—
0
22
0
28
0.00
0.99
0.0
2.0
—
—
—
0
0
0
28
0.00
0.99
0.0
1.9
—
—
—
0
0
7
121
0.54
0.86
8.4
6.3
29.27
30.81
s
—
7
121
0
25
0.00
0.80
0.0
4.1
—
27.95
—
0
25
0
27
0.00
0.79
0.0
1.6
—
—
—
0
0
0
27
0.00
0.79
0.0
2.0
—
—
—
0
0
22
284
0.70
0.70
18.2
12.4
1.23
1.22
mmol/l
0.70
22
269
0
21
0.00
0.61
0.0
1.7
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
12
85
1.48
0.50
10.7
10.6
20.99
24.18
mmol/l
2.04
12
85
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
13.25
—
0
16
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
41.11
—
0
18
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.0
—
—
—
0
0
6
87
0.67
0.35
1.2
2.0
—
—
—
0
0
12
94
1.32
0.30
18.8
17.7
23.90
25.45
mmol/l
0.62
12
94
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
33
358
0.87
0.19
10.3
7.5
10.13
5.78
mmol/l
3.91
33
341
13
118
1.12
0.07
16.9
11.2
1.16
1.24
mmol/l
0.52
13
111
0
6
0.00
0.00
0.0
3.0
—
119.67
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
964.33
—
0
6
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
9.0
—
22.12
—
0
8
0
8
0.00
0.00
0.0
1.0
—
90.75
—
0
8
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
6.44
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.9
—
61.43
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
7
78
0.89
-0.00
17.7
12.2
104.57
105.86
mmol/l
—
7
78
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
-0.00
0.0
2.7
—
124.43
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
7.09
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.2
—
8.72
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
-0.00
0.0
1.0
—
116.80
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
16.16
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint T1D_STRICT2 and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have T1D_STRICT2.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: T1D_STRICT2 – Type 1 diabetes, strict definition, subgroup 2
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data